Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Queen Mary University Of London has 6 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 6 distinct examiners and 6 distinct art units, showing a fully distributed set of examination assignments. This structure calls for centralized portfolio tracking paired with independent analysis of each technical record.
BANERJEE, KOYELI is the busiest examiner, with 1 pending matter. No identified examiner has multiple pending matters, so prosecution strategy should emphasize consistency in core positions while adapting claim arguments and evidence to each art-unit context.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §103 only | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| MCCOLLUM, ANDREA K | 1 | 60.2% | +33.3% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 73d overdue |
| 18292770 | SYNDECAN PEPTIDES | BANERJEE, KOYELI | — |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
| 17628951 | METHODS FOR DIAGNOSING CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 73d overdue |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 38d overdue |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 8d overdue |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1643 | 1 |
| 1674 | 1 |
| 1614 | 1 |
| 1619 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292770 | SYNDECAN PEPTIDES | BANERJEE, KOYELI | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 1674 | §102§112 | Final Rejection | 73d overdue | Pending | Jun 29, 2023 |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 1614 | §103 | Final Rejection | 38d overdue | Pending | Jun 21, 2023 |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 1619 | §103 | Final Rejection | 8d overdue | Pending | Jun 09, 2023 |
| 17628951 | METHODS FOR DIAGNOSING CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §101§103§112 | Non-Final OA | — | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQueen Mary University Of London has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Koyeli Banerjee has the most, with 1 of Queen Mary University Of London's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
